Long-term Survival After Adjuvant Therapy for Stage 2 Breast Cancer
Author Information
Author(s): J.W. Gamel, R.L. Vogel
Primary Institution: Veterans Administration Medical Center and University of Louisville School of Medicine
Hypothesis
Can combining survival models improve the estimation of long-term survival following adjuvant therapy for stage 2 breast cancer?
Conclusion
The study found that increasing the cured fraction has a greater long-term impact on survival than increasing median survival time among uncured patients.
Supporting Evidence
- Deaths from breast cancer follow a lognormal distribution.
- An increase in cured fraction significantly improves long-term survival for younger patients.
- Non-parametric tests may not accurately reflect the effectiveness of treatments based on short-term survival rates.
Takeaway
This study shows that for breast cancer patients, being cured is more important for long-term survival than just living longer with the disease.
Methodology
The study used a combination of lognormal survival models to estimate the impact of treatment on overall long-term survival.
Potential Biases
Non-parametric methods may lead to misinterpretation of treatment effectiveness based on short-term survival rates.
Limitations
The study relies on assumptions about the distribution of survival times and may not account for all variables affecting survival.
Participant Demographics
The study analyzed data from women diagnosed with stage 2 breast cancer, focusing on different age groups.
Want to read the original?
Access the complete publication on the publisher's website